Cellectar Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLRB research report →
Companywww.cellectar.com
Cellectar Biosciences, Inc. , a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM.
- CEO
- James V. Caruso
- IPO
- 2005
- Employees
- 11
- HQ
- Florham Park, NJ, US
Price Chart
Valuation
- Market Cap
- $10.12M
- P/E
- -0.64
- P/S
- 0.00
- P/B
- 2.85
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -264.79%
- ROIC
- -358.20%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-21,791,037 · 51.12%
- EPS
- $-8.35 · 77.14%
- Op Income
- $-22,979,844
- FCF YoY
- 51.51%
Performance & Tape
- 52W High
- $20.70
- 52W Low
- $2.43
- 50D MA
- $2.93
- 200D MA
- $3.67
- Beta
- 0.43
- Avg Volume
- 1.02M
Get TickerSpark's AI analysis on CLRB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 7, 26 | Longcor Jarrod | buy | 26,040 |
| May 7, 26 | Longcor Jarrod | buy | 8,680 |
| May 7, 26 | CARUSO JAMES V | buy | 26,040 |
| May 7, 26 | CARUSO JAMES V | buy | 8,680 |
| Dec 12, 25 | NEIS JOHN | sell | 198 |
| Jul 2, 25 | CARUSO JAMES V | buy | 10,000 |
| Jul 2, 25 | CARUSO JAMES V | buy | 10,000 |
| Jul 2, 25 | Longcor Jarrod | buy | 10,000 |
| Jul 2, 25 | Longcor Jarrod | buy | 10,000 |
| Jul 2, 25 | Kolean Chad J | buy | 5,000 |
Our CLRB Coverage
We haven't published any research on CLRB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CLRB Report →